Al Musella, DPM President, Musella Foundation For Brain Tumor Research & Information, Inc.

  •  

    How an Expert Would Treat His Own Glioblastoma

    With: Al Musella, DPM

    Two years ago, our Curious Dr. George asked Al Musella, DPM, what he would do if he were diagnosed with glioblastoma multiforme (GBM). Here, he revisits that question. Dr. Musella is President of the Musella Foundation For Brain Tumor Research & Information, Inc. Curious Dr. George: You direct an established foundation that supports research and information about brain tumors. What would you do if… Read more »

  •  

    Options to Treat a Glioblastoma

    With: Al Musella, DPM

    Please see our updated version of this article from Oct 1, 2020. A Q&A with Al Musella, DPM, President, Musella Foundation For Brain Tumor Research & Information, Inc., Hewlett, NY; email: musella@virtualtrials.com, phone: 888-295-4740 Q: You direct an established foundation that supports research and information about brain tumors. What would you do if you yourself were diagnosed with a glioblastoma multiforme (GBM)? A: Now… Read more »

  •  

    Proposed FDA “Conditional Approval”- More Details

    With: Marty Tenenbaum, PhDAl Musella, DPM

    A Q&A with Al Musella, DPM, President, Musella Foundation For Brain Tumor Research & Information, Inc., Hewlett, NY, and Marty Tenenbaum, PhD, Founder and Chair, Cancer Commons, Los Altos, CA Originally published May 10, 2017 Q: Your April 5, 2017 blog post that proposed a new “Conditional” category for FDA drug approval elicited a number of positive and negative responses. Please explain the proposal in more detail… Read more »

  •  

    A Proposed New FDA Drug Approval Pathway: “Conditional”

    With: Marty Tenenbaum, PhDAl Musella, DPM

    A Q&A with Al Musella, DPM, President, Musella Foundation For Brain Tumor Research & Information, Inc., Hewlett, NY, and Marty Tenenbaum, PhD, Founder and Chair, Cancer Commons, Los Altos, CA Originally published April 5, 2017 Q: The delay time from discovery/observation, through validation to approval and distribution/use of new cancer treatments remains excessive. With promising experimental treatments, advanced computer technology and biostatistics, creative alternatives… Read more »